Icsm Defer Tt Elevated Psa Or Nodules

---
name: icsm-defer-tt-elevated-psa-or-nodules
description: Recommends postponing testosterone initiation and pursuing MRI or biopsy when PSA is elevated or a prostate nodule is detected on digital rectal examination; if evaluation shows no cancer, testosterone therapy may be considered. Triggered by clinician findings of elevated PSA (>4 ng/mL) or a palpable prostate nodule during DRE, prompting the question of whether to hold testosterone until prostate cancer is ruled out.
---

# Defer testosterone therapy until prostate evaluation if PSA elevated or nodules present

## STEP 1 — Gather Information
Collect symptoms of hypogonadism, obtain morning total testosterone, perform digital rectal examination (DRE), and measure serum PSA.  
→ Proceed to evaluate PSA and DRE findings.

## STEP 2 — Rule In / Rule Out
Is PSA >4 ng/mL (or age‑adjusted threshold) or is a prostate nodule palpable on DRE?  
- If yes → proceed to Step 3.  
- If no → testosterone therapy may be considered after confirming hypogonadism.  
→ Decision based on PSA/DRE results.

## STEP 3 — Classify or Stratify
If PSA elevated or nodule present, obtain prostate MRI and/or targeted biopsy to rule out malignancy.  
→ Proceed to prostate imaging/biopsy.

## STEP 4 — Decide
If evaluation shows no cancer, testosterone therapy may be initiated; if cancer is diagnosed, refer to oncology and defer testosterone.  
→ Initiate testosterone only after negative prostate evaluation; otherwise refer for cancer management.

## Clinical Guardrails / Mimics / Pitfalls
Do not start testosterone in men with elevated PSA or nodule without urologic assessment; do not rely on PSA alone without DRE; do not ignore nodules; consider that PSA can be elevated by BPH, infection, or recent ejaculation; ensure biopsy is performed if MRI suspicious; avoid testosterone in known prostate cancer.

## Concrete Clinical Example
A 58‑year‑old man presents with low libido and morning total testosterone 8 nmol/L. DRE reveals a firm nodule and PSA is 5.2 ng/mL. Testosterone is deferred; prostate MRI shows a suspicious lesion, biopsy confirms benign prostatic hyperplasia. After negative evaluation, testosterone therapy is started.

**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), Mohit Khera et al., 2025, DOI: 10.1093/sxmrev/qeaf036